Chan Michael, Kakitsubata Yuhei, Hayashi Tomoko, Ahmadi Alast, Yao Shiyin, Shukla Nikunj M, Oyama Shin-Ya, Baba Akihito, Nguyen Brandon, Corr Maripat, Suda Yasuo, Carson Dennis A, Cottam Howard B, Wakao Masahiro
Moores Cancer Center, University of California, San Diego , 9500 Gilman Drive, La Jolla, California 92093-0695, United States.
Department of Chemistry, Kagoshima University , 1-21-40 Kohrimoto, 890-0065, Kagoshima, Japan.
J Med Chem. 2017 Nov 22;60(22):9142-9161. doi: 10.1021/acs.jmedchem.7b00797. Epub 2017 Nov 3.
Previous high throughput screening studies led to the discovery of two novel, nonlipid-like chemotypes as Toll-like receptor 4 (TLR4) agonists. One of these chemotypes, the pyrimido[5,4-b]indoles, was explored for structure-activity relationship trends relative to production of TLR4 dependent cytokines/chemokines, resulting in a semioptimized lead (compound 1) that provided a starting point for further optimization studies. In this report, compounds belonging to three areas of structural modification were evaluated for biological activity using murine and human TLR4 reporter cells, primary murine bone marrow derived dendritic cells, and human peripheral blood mononuclear cells. The compounds bearing certain aryl groups at the C8 position, such as phenyl (36) and β-naphthyl (39), had potencies significantly greater than compound 1. Compound 36 displayed human TLR4 agonist activity at submicromolar concentrations. The computational analysis suggests that the improved potency of these C8-aryl derivatives may be the result of additional binding interactions at the interface of the TLR4/myeloid differentiation protein-2 (MD-2) complex.
先前的高通量筛选研究发现了两种新型的、非脂质类化学型作为Toll样受体4(TLR4)激动剂。其中一种化学型,即嘧啶并[5,4-b]吲哚,针对与TLR4依赖性细胞因子/趋化因子产生相关的构效关系趋势进行了探索,从而得到了一个半优化的先导化合物(化合物1),为进一步的优化研究提供了起点。在本报告中,使用小鼠和人类TLR4报告细胞、原代小鼠骨髓来源的树突状细胞以及人类外周血单核细胞,对属于三个结构修饰区域的化合物进行了生物活性评估。在C8位置带有某些芳基的化合物,如苯基(36)和β-萘基(39),其效力明显高于化合物1。化合物36在亚微摩尔浓度下表现出人类TLR4激动剂活性。计算分析表明,这些C8-芳基衍生物效力的提高可能是由于在TLR4/髓样分化蛋白-2(MD-2)复合物界面处存在额外的结合相互作用。